ACIU ACIU
Company Profile ↓Company Overview
ACIU (ACIU) is a publicly traded company listed on with a market capitalization of $257.95M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.10.
Recent Developments
- Dec 2025 Revenue of $3.57M (-86.9% YoY); net profit $-70.45M.
- Trailing 12 Months Year-on-year growth — revenue -86.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -3.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -3.17% |
| 1 Year: | -86.92% |
Stock Price Performance
| 1 Year: | +4.33% |
| 6 Months: | -31.44% |
| 3 Months: | -23.92% |
| 1 Month: | -9.84% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.21 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -3.2% CAGR over 5 years.
- Trading 42.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 990.00K | 1.31M | 939.00K | 338.00K | 1.12M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 20.36M | 20.69M | 16.64M | 14.74M | 15.91M |
| Operating Income | - | -19.37M | -19.39M | -15.70M | -14.41M | -14.79M |
| EBITDA | - | -18.36M | -20.52M | -15.20M | -13.68M | -14.74M |
| Interest Expense | - | 54.00K | 50.00K | 46.00K | 42.00K | 65.00K |
| Pretax Income | - | -19.03M | -21.19M | -15.86M | -14.37M | -14.80M |
| Tax Provision | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | - | -19.03M | -21.19M | -15.86M | -14.37M | -14.80M |
| Diluted EPS | - | -0.19 | -0.21 | -0.16 | - | -0.15 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 3.94M | 14.80M | 27.31M | 3.57M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 74.78M | 68.42M | 79.69M | 72.44M |
| Operating Income | -70.85M | -53.62M | -52.38M | -68.86M |
| EBITDA | -68.03M | -51.83M | -48.62M | -67.75M |
| Interest Expense | 355.00K | 176.00K | 133.00K | 191.00K |
| Pretax Income | -70.74M | -54.22M | -50.91M | -70.45M |
| Tax Provision | 13.00K | 10.00K | 3.00K | 0 |
| Net Income | -70.75M | -54.23M | -50.92M | -70.45M |
| Diluted EPS | -0.85 | -0.64 | -0.51 | -0.70 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 185.94M | 182.81M | 230.91M | 154.25M |
| Current Assets | - | 128.09M | 125.15M | 171.99M | 96.72M |
| Cash & Equivalents | - | 31.59M | 78.49M | 36.27M | 26.80M |
| Inventory | - | - | - | - | - |
| Receivables | - | 0 | 14.80M | 0 | - |
| Total Liabilities | - | 16.95M | 22.17M | 118.64M | 109.37M |
| Current Liabilities | - | 11.48M | 13.58M | 100.84M | 94.69M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 2.80M | 3.50M | 5.43M | 4.54M |
| Total Equity | - | 168.99M | 160.64M | 112.27M | 44.88M |
| Shares Outstanding | - | 89.83M | 104.44M | 111.31M | 112.64M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -73.57M | -60.41M | 65.84M | -69.26M |
| Investing Cash Flow | - | 23.76M | 65.64M | -105.29M | 63.54M |
| Financing Cash Flow | - | -1.35M | 43.25M | -1.12M | -1.02M |
| Capital Expenditure | - | -1.24M | -801.00K | -576.00K | -900.00K |
| Free Cash Flow | - | -74.81M | -61.21M | 65.27M | -70.16M |
| Net Change in Cash | - | -51.15M | 48.49M | -40.57M | -6.74M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | -1,800.4% | -362.3% | -191.8% | -1,927.3% |
| Net Margin % | -1,798.0% | -366.4% | -186.4% | -1,971.6% |
| ROE % | -41.9% | -33.8% | -45.4% | -157.0% |
| ROCE % | -40.6% | -31.7% | -40.3% | -115.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ACIU
AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates
AC Immune (ACIU) delivered earnings and revenue surprises of +113.64% and +1,812.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
AC Immune First Half 2026 Financial and Corporate Update
AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-term…
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics…
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three Alzheimer’s disease (AD) cohorts in ABATE…
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?
ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.…
June 2026 Penny Stocks To Watch For Potential Growth
Over the last 7 days, the market has remained flat, but it is up 24% over the past year, with earnings expected to grow by 19% per annum over the next few years. For investors willing to explore beyond well-known stocks, penny stocks — ofte…
ACIU — Frequently Asked Questions
What is the current share price of ACIU?
As of 2026-08-05 17:25 PDT, ACIU trades at $2.29 on NASDAQ/NYSE. Its 52-week range is $2.04 to $3.99.
What is the market capitalisation of ACIU?
ACIU has a market capitalisation of $257.95M on NASDAQ/NYSE.
What is the P/E ratio of ACIU?
ACIU trades at a trailing price-to-earnings (P/E) ratio of -3.27. Its price-to-book (P/B) ratio is 5.75.
Is ACIU a good stock to buy?
This page provides a data-driven analysis of ACIU, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.